ADVERTISEMENT
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.

disease & medicine, pharma

an illustration showing amyloid plaques around brain cells
Biogen Presents Data on Efficacy of Alzheimer’s Drug
Shawna Williams | Dec 6, 2019 | 2 min read
The company and its partner halted two clinical trials for futility early this year, but now say they’ll seek approval for aducanumab.
gene therapy approval used manipulated data
Some Data Backing Novartis Gene-Therapy Approval Manipulated: FDA
Nicoletta Lanese | Aug 7, 2019 | 2 min read
The agency is now evaluating the implications of the corrupted data behind Zolgensma and whether to “take action” against the pharmaceutical company.
How K2 and Other Synthetic Cannabinoids Got Their Start in the Lab
Ashley Yeager | Nov 27, 2018 | 7 min read
Originally intended for basic neuroscience research, the drugs were ultimately hijacked for illicit recreational use.
Serum Survey Reveals Protein Patterns of Ill Health
Ruth Williams | Aug 2, 2018 | 3 min read
Analyses of blood from thousands of people show distinct protein profiles are linked to complex diseases of aging.
FDA Approves First Marijuana-Derived Drug
Shawna Williams | Jun 25, 2018 | 2 min read
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
ADVERTISEMENT